A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

References

• Cory JG, Sato A. Regulation of ribonucleotide reductase activity in mammalian cells. Mol Cell Biochem. 1983;53:257–266.
   PubMed Web of Science ®Google Scholar
• Thelander L, Berg P. Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase. Mol Cell Biol. 1986;6:3433–3442.
   PubMed Web of Science ®Google Scholar
• Chang CH, Cheng YC. Substrate specificity of human ribonucleotide reductase from Molt-4F cells. Cancer Res. 1979;39:5081–5086.
   PubMed Web of Science ®Google Scholar
• Thelander M, Graslund A, Thelander L. Subunit M2 of mammalian ribonucleotide reductase. J Biol Chem. 1985;260:2737–2741.
   PubMed Web of Science ®Google Scholar
• Yen Y, Grill SP, Dutschman GE, et al. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res. 1994;54:3686–3691.
   PubMed Web of Science ®Google Scholar
• Shao J, Zhou B, Chu B, et al. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets. 2006;6:409–431.
   PubMed Web of Science ®Google Scholar
• Richards GJ, Chambers RG. Hydroxyurea in the treatment of neoplasms of the head and neck. A resurvey. Am J Surg. 1973;126:513–518.
   PubMed Web of Science ®Google Scholar
• Piver MS, Barlow JJ, Vongtama V, et al. Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. Am J Obstet Gynecol. 1977;129:379–383.
   PubMed Web of Science ®Google Scholar
• Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol. 1992;19:11–19.
   PubMed Web of Science ®Google Scholar
• Lien EJ. Ribonucleotide reductase inhibitors as anticancer and antiviral agents. Prog Drug Res. 1987;31:10–26.
   Google Scholar
• Elford HL. Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun. 1968;33:129–135.
   PubMed Web of Science ®Google Scholar
• Finch RA, Liu M, Grill SP, et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor ribonucleotide reductase activity and broad spectrum antitumor activity. Biochem Pharm. 2000;59:983–991.
   PubMed Web of Science ®Google Scholar
• Choy BK, McClarty GA, Chan AK, et al. Molecular mechanisms, of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations. Cancer Res. 1988;48:2029–2035.
   PubMed Web of Science ®Google Scholar
• Tagger AY, Wright JA. Molecular and cellular characterization of drug resistant hamster cell lines with alterations in ribonucleotide reductase. Int J Cancer. 1988;42:760–766.
   PubMed Web of Science ®Google Scholar
• Engstrom Y, Eriksson S, Jildevik I, et al. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem. 1985;260:9114–9116.
   PubMed Web of Science ®Google Scholar
• Björklund S, Skog S, Tribukait B, et al. S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry. 1990;29:5452–5458.
   PubMed Web of Science ®Google Scholar
• Ali MA, McWeeney D, Milosvljevic A, et al. Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunit from herpes simplex virus type 2. Proc Natl Acad Sci USA. 1991;88:8257–8261.
   PubMed Web of Science ®Google Scholar
• Björklund S, Hjortsberg K, Johansson E, et al. Structure and promoter characterization of the gene encoding the large subunit (R1 protein) of mouse ribonucleotide reductase. Proc Natl Acad Sci USA. 1993;90:11322–11326.
   PubMed Web of Science ®Google Scholar
• Hurta RA, Wright JA. Mammalian drug resistant mutants with multiple gene amplifications: genes encoding the M1 component of ribonucleotide reductase, the M2 component of ribonucleotide reductase, ornithine decarboxylase, p5-8, the H-subunit of ferritin and the L-subunit of ferritin. Biochem Biophys Acta. 1990;1987:165–172.
   Google Scholar
• Luo JH, Smith CC, Kulka M, et al. A truncated protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) expressed in Escherichia coli. J Biol Chem. 1991;266:20976–20983.
   PubMed Web of Science ®Google Scholar
• Jones C, Zhu F, Dhanwada KR. Analysis of a herpes simplex virus 2 fragment from the open reading frame of the large subunit of ribonucleotide reductase with transcriptional regulatory activity. DNA Cell Biol. 1993;12:127–137.
   PubMed Web of Science ®Google Scholar
• Desai P, Ramakrishnan R, Lin ZW, et al. The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection. J Virol. 1993;67:6125–6135.
   PubMed Web of Science ®Google Scholar
• Lankinen H, Everett R, Cross A, et al. Epitope mapping identifies an exposed loop between the unique amino-and conserved carboxy-domains of the large subunit of herpes simplex virus type 1 ribonucleotide reductase. J Gen Virol. 1993;74:1871–1877.
   PubMed Web of Science ®Google Scholar
• Fan H, Villegas C, Huang A, et al. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res. 1998;58:1650–1653.
   PubMed Web of Science ®Google Scholar
• Huang A, Fan H, Taylor WR, et al. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Cancer Res. 1997;57:4876–4881.
   PubMed Web of Science ®Google Scholar
• Lee Y, Vassilakos A, Feng N, et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res. 2003;63:2802–2811.
   PubMed Web of Science ®Google Scholar
• Desai AA, Schilsky RL, Young A, et al. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005;16:958–965.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Wei X, Dai G, Marcucci G, et al. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices. Pharm Res. 2006;23:1251–1264.
   PubMed Web of Science ®Google Scholar
• Juhasz A, Vassilakos A, Chew HK, et al. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep. 2006;15:1299–1304.
   PubMed Web of Science ®Google Scholar
• Ferdinandi ES, Vassilakos A, Lee Y, et al. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2. Cancer Chemother Pharmacol. 2011;68:193–205.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Desai AA, Quinn DI, et al. A phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008;61:689–694.
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Canil CM, Chi KN, et al. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2011;67:927–933.
   PubMed Web of Science ®Google Scholar
• Leighl NB, Laurie SA, Chen XE, et al. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. J Thorac Oncol. 2009;4:1163–1169.
   PubMed Web of Science ®Google Scholar
• Shibata SI, Doroshow JH, Frankel P, et al. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2009;64:1149–1155.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Plunkett W, Kantarjian H, et al. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998;16:2321–2331.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Fracasso PM, Kantarjian HM, et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003;27:1077–1083.
   PubMed Web of Science ®Google Scholar
• Klisovic RB, Blum W, Wei X, et al. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res. 2008;14:3889–3895.
   PubMed Web of Science ®Google Scholar
• Klisovic RB, Blum W, Liu Z, et al. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2014;55:1332–1336.
   PubMed Web of Science ®Google Scholar